Revolution Medicines, Inc. (NASDAQ:RVMD) Q3 2022 Earnings Conference Call November 7, 2022 4:30 PM ET
Company Participants
Margaret Horn - Chief Operating Officer
Mark Goldsmith - Chairman & Chief Executive Officer
Jack Anders - Senior Vice President of Finance & Principal Accounting Officer
Steve Kelsey - President of R&D
Conference Call Participants
Alec Stranahan - Bank of America
Faisal Khurshid - SVB Securities
Eric Joseph - JPMorgan
Marc Frahm - Cowen
Michael Schmidt - Guggenheim Partners
Chris Shibutani - Goldman Sachs
Jay Olson - Oppenheimer
Operator
Good day and thank you for standing by. Welcome to the Revolution Medicines Third Quarter 2022 Earnings Webcast. [Operator Instructions]
I would now like to hand the conference over to Peg Horn, Revolution Medicine's Chief Operating Officer for opening remarks. Peg, you may begin.
Margaret Horn
Thank you and welcome, everyone, to our third-quarter earnings call. Joining me on today's call are Dr. Mark Goldsmith, Revolution Medicine's Chairman and Chief Executive Officer; Dr. Steve Kelsey, the company's President, Research and Development; and Jack Anders, our Chief Financial Officer.
As we begin, I would like to note that our presentation will include statements regarding the current beliefs of the company with respect to our business that constitutes forward-looking statements within the meaning of the Private Securities Litigation Reform Act. These statements are subject to a number of assumptions, risks and uncertainties. Actual results may differ materially from these statements. And except as required by law, the company undertakes no obligation to revise or update any forward-looking statements. I encourage you to review the legal disclaimer slide of our corporate presentation or the earnings press release as well as all of the company's filings with the SEC concerning these and other matters.
With that, I will turn the call over to Dr. Mark Goldsmith, Revolution Medicines Chairman and Chief Executive Officer. Mark?
Mark Goldsmith
Good afternoon and thank you for joining us. Today, I'll provide an update on our corporate progress and our Chief Financial Officer, Jack Anders, will provide highlights of our financial results.
In the third quarter, Revolution Medicines continued advancing our pipeline of groundbreaking RAS(ON) inhibitors on behalf of patients with a wide range of RAS-addicted cancers which represent 30% of all human cancers. We are building momentum with our RAS(ON) inhibitor pipeline, having now advanced 2 RAS(ON) inhibitor development candidates into Phase I/Ib dose-escalation trials. With the transition of these RAS(ON) inhibitors into early clinical development, we now have 4 compounds from our cohesive portfolio of RAS cancer-targeted therapeutics in human studies. This progress across our pipeline sets up an exciting and potentially data-rich 2023. I'll now review a number of key achievements that reflect this recent progress regarding our pipeline of RAS(ON) inhibitors and RAS Companion inhibitors.